Join us Thursday, May 4th, 2017
Are you interested in understanding how liquid biopsy can be used to monitor cancer progression? Do you want to learn about the types of tests that are being developed in this area, how they work and if they really offer useful insight to understanding cancer progression, monitoring and treatment?
Join us on Thursday, May 4th, 2017, at 1:00 pm EDT, 10:00 am PDT, 6:00 pm GMT and 7:00 pm CEST, as Dr. Lawrence LaPointe, CEO, Director and Co-Founder of Clinical Genomics and Dr. Martin Horlitz, Associate Director New Product Quality Assurance at QIAGEN, will present a special one hour webinar, hosted by GenomeWeb, entitled “Liquid Biopsies for Improved Recurrence Monitoring in Colorectal Cancer”.
Analysis of circulating tumor DNA (ctDNA) has the potential to improve detection and monitoring of cancers to significantly impact patient outcomes. This is especially important for cancers with a high rate of recurrence, such as colorectal cancer, where 30–40% of cases recur. However, the only currently available monitoring blood test misses 74% of resectable recurrences.
In this webinar, Dr. Lawrence LaPointe will discuss how his team is working with QIAGEN to develop a ctDNA test for colorectal cancer recurrence monitoring. Additionally, Dr. Martin Horlitz will briefly share how QIAGEN’s ctDNA extraction chemistries are compliant with ISO and IVD quality guidelines.